Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.
The … Read more
By Matthew Fowler
xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.
The FDA granted the investigational new drug application for the ERK
By Liam Drew
PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more
No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.
By Charles Bankhead
An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University … Read more
Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more
Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more
When a loved one is diagnosed with ovarian cancer, it has a profound effect on their lives and their families’ lives. As quickly as the patient receives her diagnosis, her family members immediately slip into caregivers’ roles, often without warning … Read more
By Leah Lawrence
A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more
By Susan Moench, PhD, PA-C
Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more
By Hannah Slater
The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.
The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more
San Diego’s Teal Women Honored in Historic Gesture in Support of Ovarian Cancer Survivors
September is National Ovarian Cancer Awareness Month and, in recognition, the County of San Diego Administration Center building will be turning its lights the color teal.
… Read moreA recent finding by researchers at UBC’s faculty of medicine and the BC Cancer Research Institute (BCCRI) may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer.
Small cell carcinoma of the … Read more
By Sarah Williams
For patients with stage III epithelial ovarian cancer, adding hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) increases survival compared with PCS alone, according to results of a retrospective study now published in JAMA Network Open… Read more
A Scripps Research team reports the discovery of a molecule that can activate a natural immune-boosting protein called STING. The findings mark a key advance in the field of oncology, as the STING protein is known for its strong antitumor … Read more
A global team of medical researchers led by UNSW have developed a test that could help to predict survival for women diagnosed with ovarian cancer, and pave the way towards personalised treatment.
A tumour test could help to identify ovarian … Read more
By Luke Harold
As chairman and CEO of CalciMedica, Rachel Leheny is overseeing the development of a potential treatment for organ damage caused by COVID-19 pneumonia.
“Our lead compound Auxora is in clinical development in COVID-19 pneumonia,” said Leheny, who … Read more
By Christina Bennett, MS
Patients with LGSC also had a significantly lower partial response rate with neoadjuvant therapy compared with patients with HGSC.
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy,
New “Caring For Her” program facilitates access to clinical trials and psychosocial support services for women with ovarian cancer.
Be The Difference Foundation today announced the launch of its “Caring For Her” program in partnership with Mary Crowley Cancer Research
Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.
However, recent immunotherapy use … Read more
